Episode Details

Yeztugo, a new HIV prevention injection, has been approved by the FDA. Gilead Sciences lenacapavir, marketed as Yeztugo, offers six-month protection without daily pills. Clinical trials show over ninety-nine percent effectiveness. Mark Moeremans, CEO of Spectrum Health, will be the first to receive the injection, highlighting its potential. Experts believe this could revolutionize HIV prevention globally, addressing adherence issues. Clinics are preparing for increased demand, anticipating lives saved and transmission rates reduced, particularly in vulnerable communities.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/1c3ba1e544d12272